Drugs Information:
Tafamidis
Basic Information
|
||
ID | DDInter1737 | |
Drug Type | small molecule | |
Molecular Formula | C14H7Cl2NO3 | |
Molecular Weight | 308.116 | |
CAS Number | 594839-88-0 | |
Description | Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal.[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280] | |
ATC Classification | N07XX08 | |
IUPAC Name | 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid | |
InChI | TXEIIPDJKFWEEC-UHFFFAOYSA-N | |
Canonical SMILES | OC(=O)C1=CC=C2N=C(OC2=C1)C1=CC(Cl)=CC(Cl)=C1 | |
Useful Links | DrugBank ChEBI PubChem Substance KEGG Drug ChemSpider BindingDB Wikipedia ChEMBL ZINC |
Interactions with
Tafamidis
Filter:
Severity level | ID | Name | Mechanism | Detail |
---|
Interactions with diseases
Filter:
Severity level | Disease name | Text | References |
---|
Interactions with foods
Filter:
Severity level | Food name | Description | Management | Mechanism | References |
---|
Interactions with compound preparation
Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
---|